Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vaccinex Inc (VCNX)

Vaccinex Inc (VCNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vaccinex Inc 1895 MOUNT HOPE AVENUE ROCHESTER NY 14620 USA

www.vaccinex.com Employees: 40 P: 585-271-2700 F: 585-271-2765

Description:

Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company's product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York.

Key Statistics

Overview:

Market Capitalization, $K 5,460
Enterprise Value, $K 4,030
Shares Outstanding, K 1,728
Annual Sales, $ 570 K
Annual Net Income, $ -20,250 K
Last Quarter Sales, $ 230 K
Last Quarter Net Income, $ -5,630 K
EBIT, $ -21,610 K
EBITDA, $ -21,490 K
60-Month Beta 0.98
% of Insider Shareholders 51.50%
% of Institutional Shareholders 50.11%
Float, K 838
% Float 48.50%
Short Volume Ratio 0.60

Growth:

1-Year Return -75.04%
3-Year Return -99.13%
5-Year Return -99.70%
5-Year Revenue Growth -20.83%
5-Year Earnings Growth 95.99%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -3.10 on 08/14/24
Next Earnings Date 11/18/24 [--]
Earnings Per Share ttm -60.71
EPS Growth vs. Prev Qtr 26.45%
EPS Growth vs. Prev Year 85.06%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-14 on 02/20/24

VCNX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -392.17%
Profit Margin % -3,552.63%
Debt/Equity -0.02
Price/Sales 11.05
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.81
Interest Coverage -1.94
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar